Why Breztri Aerosphere Is Not Approved for Asthma

When it comes to managing respiratory diseases, inhalers play a crucial role in improving patients’ quality of life. While some inhalers are approved for multiple conditions, others are specifically tailored to treat a particular disease. One such medication is Breztri Aerosphere, which is commonly prescribed for chronic obstructive pulmonary disease (COPD) but not for asthma.

Many patients and even some healthcare providers may wonder: Why is Breztri not used for asthma? The answer lies in its composition, mechanism of action, regulatory approvals, and clinical guidelines. In this article, we will explore why Breztri is not recommended for asthma treatment, how asthma differs from COPD, and what alternative options are available for asthma patients.

Understanding Breztri Aerosphere

Three active components make up the triple-therapy inhaler Breztri Aerosphere:

• Budesonide (ICS – Inhaled Corticosteroid): Helps reduce inflammation in the lungs.
• Formoterol (LABA – Long-Acting Beta-Agonist): Relaxes the muscles in the airways for easier breathing.
• Glycopyrrolate (LAMA – Long-Acting Muscarinic Antagonist): Helps reduce mucus production and further relax airway muscles.

This combination is primarily designed to manage COPD, a chronic lung condition often caused by smoking or environmental exposure. The presence of a LAMA in the inhaler is a key reason why it is not suitable for asthma patients.

Key Differences Between Asthma and COPD

To understand why Breztri is not used for asthma, it is important to recognize how asthma and COPD differ:

Nature of the Disease:

• Asthma is an inflammatory disease characterized by episodes of airway narrowing that are reversible with treatment.
• COPD is a progressive disease where airway damage is often irreversible due to chronic inflammation and lung tissue destruction.

Causes:

• Asthma is often triggered by allergens, environmental factors, or respiratory infections.
• COPD is mainly caused by smoking and long-term exposure to lung irritants.

Treatment Approaches:

• Asthma treatment typically involves inhaled corticosteroids (ICS) and LABA without a LAMA in most cases.
• COPD treatment often requires ICS, LABA, and LAMA, making triple therapy like Breztri more relevant for COPD.

Why Breztri Is Not Approved for Asthma

Despite its effectiveness for COPD, Breztri has not received regulatory approval for asthma due to the following reasons:

FDA Approval and Clinical Trials

Breztri has been FDA-approved only for COPD, meaning its safety and efficacy for asthma patients have not been thoroughly studied. Regulatory approvals for medications depend on extensive clinical trials that demonstrate their effectiveness for specific conditions. Since Breztri has not undergone such trials for asthma, it remains unapproved and untested for asthma patients.

Role of LAMA in COPD vs. Asthma

One of the most significant reasons why Breztri is not used for asthma is the presence of glycopyrrolate (LAMA).

• In COPD, LAMAs help reduce mucus production and further relax the airway muscles, improving symptoms.
• In asthma, LAMAs are not first-line treatments and are only considered for severe cases where ICS-LABA therapy is insufficient.
• Overuse of LAMA in asthma could lead to increased side effects such as dry mouth, urinary retention, and an increased risk of infections.

Guidelines for Asthma Treatment

International asthma treatment guidelines, such as those from the Global Initiative for Asthma (GINA), recommend ICS-LABA combinations as the primary treatment for moderate to severe asthma. Triple therapy (ICS-LABA-LAMA) is only recommended when conventional treatments fail, and it is typically given in a different inhaler combination than Breztri.

Risk of Asthma Exacerbation

Since Breztri has not been tested in asthma populations, its effect on asthma exacerbations remains unclear. Asthma patients who rely on inappropriate medications may experience:

• Increased risk of asthma attacks.
• Reduced effectiveness in managing airway inflammation.
• Unnecessary side effects from medications that are not required for asthma treatment.

Alternative Treatment Options for Asthma

Since Breztri is not recommended for asthma, patients have several other effective options, including:

ICS-LABA Combination Inhalers (First-Line Treatment for Moderate to Severe Asthma)

• Symbicort (Budesonide/Formoterol)
• Advair (Fluticasone/Salmeterol)
• Dulera (Mometasone/Formoterol)

These inhalers provide anti-inflammatory benefits and bronchodilation without the unnecessary addition of LAMA.

ICS-Only Inhalers (For Mild Asthma)

• Pulmicort (Budesonide)
• Flovent (Fluticasone)
• QVAR (Beclomethasone)

These are suitable for patients with mild, well-controlled asthma.

LAMA as an Add-On Therapy (For Severe Asthma Cases Only)

• Spiriva Respimat (Tiotropium) is sometimes added when ICS-LABA therapy is inadequate.

Biologic Therapies for Severe Asthma

For patients with severe, uncontrolled asthma, biologic therapies can be used:

• Dupixent (dupilumab) for eosinophilic asthma.
• Xolair (Omalizumab) for allergic asthma.
• Fasenra (Benralizumab) for severe eosinophilic asthma.

These options target specific immune pathways that contribute to asthma symptoms, offering better control for patients who do not respond to traditional inhalers.

Conclusion

Breztri Aerosphere is an effective inhaler for COPD but is not suitable or approved for asthma due to its formulation, lack of clinical trials in asthma patients, and asthma treatment guidelines. Asthma patients should stick to proven treatments like ICS-LABA inhalers, LAMA add-ons, or biologic therapies for better disease management. If you have any concerns about your asthma medication, consult your doctor for guidance.

Do you have questions about asthma treatment options? Let us know in the comments below!

FAQs